Literature DB >> 3304600

Changes in endogenous microflora among febrile granulocytopenic patients receiving empiric antibiotic therapy: implications for fungal superinfection.

E J Bow, T J Louie.   

Abstract

The ecologic effect of empiric systemic antibiotic therapy on the endogenous microflora was evaluated in 83 febrile granulocytopenic patients with cancer who were randomly allocated to receive moxalactam plus ticarcillin (45 patients) or tobramycin plus ticarcillin (38 patients) for suspected infection. Serial surveillance cultures of the nasal passages, oropharynx and feces performed twice a week showed that patients who received the former regimen had higher elimination rates and significantly lower acquisition rates (p = 0.027) for aerobic gram-negative bacilli than did patients who received the latter regimen. However, therapy with moxalactam plus ticarcillin also resulted in significantly higher acquisition rates for yeasts (p = 0.004). This was associated with a significantly higher fungal superinfection rate among these patients than among those who received tobramycin plus ticarcillin (40% v. 16%) (p less than 0.05). Moxalactam plus ticarcillin therapy created a greater microbial ecologic vacuum by the elimination of intestinal anaerobes, which, in turn, permitted fungal colonization and an increased risk of superinfection. Our results support the recommendation that an antipseudomonal penicillin plus an aminoglycoside be selected as empiric therapy for suspected infection in febrile granulocytopenic patients with cancer. Such a regimen would spare the anaerobic intestinal microflora, thereby reducing the risk of fungal colonization and infection.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3304600      PMCID: PMC1492778     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  18 in total

1.  Colonization resistance of the digestive tract of mice during systemic antibiotic treatment.

Authors:  D van der Waaij; J M Berghuis; J E Lekkerkerk
Journal:  J Hyg (Lond)       Date:  1972-12

2.  Effect of systemic antimicrobial prophylaxis on microbial flora.

Authors:  G P Bodey; B Rosenbaum; M Valdivieso; R Bolivar
Journal:  Antimicrob Agents Chemother       Date:  1982-03       Impact factor: 5.191

3.  Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia.

Authors:  P A Pizzo; K J Robichaud; F A Gill; F G Witebsky
Journal:  Am J Med       Date:  1982-01       Impact factor: 4.965

4.  Enterococcal superinfection and colonization after therapy with moxalactam, a new broad-spectrum antibiotic.

Authors:  V L Yu
Journal:  Ann Intern Med       Date:  1981-06       Impact factor: 25.391

5.  Selective elimination of Enterobacteriaceae species from the digestive tract in mice and monkeys.

Authors:  D van der Waaij; J M Berghuis-de Vries
Journal:  J Hyg (Lond)       Date:  1974-04

6.  The value of fungal surveillance cultures as predictors of systemic fungal infections.

Authors:  G R Sandford; W G Merz; J R Wingard; P Charache; R Saral
Journal:  J Infect Dis       Date:  1980-10       Impact factor: 5.226

7.  Randomized controlled trial comparing trimethoprim/sulfamethoxazole and trimethoprim for infection prophylaxis in hospitalized granulocytopenic patients.

Authors:  E J Bow; T J Louie; P D Riben; R D McNaughton; G K Harding; A R Ronald
Journal:  Am J Med       Date:  1984-02       Impact factor: 4.965

8.  Fungemia in the immunocompromised host. Changing patterns, antigenemia, high mortality.

Authors:  F Meunier-Carpentier; T E Kiehn; D Armstrong
Journal:  Am J Med       Date:  1981-09       Impact factor: 4.965

9.  Fungal infections in patients with acute leukemia.

Authors:  M W DeGregorio; W M Lee; C A Linker; R A Jacobs; C A Ries
Journal:  Am J Med       Date:  1982-10       Impact factor: 4.965

10.  In vitro activity of moxalactam against anaerobic bacteria.

Authors:  M J Gilchrist; J A Washington
Journal:  Rev Infect Dis       Date:  1982 Nov-Dec
View more
  2 in total

1.  Characterization and quantification of the fungal microbiome in serial samples from individuals with cystic fibrosis.

Authors:  Sven D Willger; Sharon L Grim; Emily L Dolben; Anna Shipunova; Thomas H Hampton; Hilary G Morrison; Laura M Filkins; George A O'Toole; Lisa A Moulton; Alix Ashare; Mitchell L Sogin; Deborah A Hogan
Journal:  Microbiome       Date:  2014-11-03       Impact factor: 14.650

2.  Fungi of the murine gut: episodic variation and proliferation during antibiotic treatment.

Authors:  Serena Dollive; Ying-Yu Chen; Stephanie Grunberg; Kyle Bittinger; Christian Hoffmann; Lee Vandivier; Christopher Cuff; James D Lewis; Gary D Wu; Frederic D Bushman
Journal:  PLoS One       Date:  2013-08-19       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.